RDGL nice news Vivos Inc Retains Well-Know OTC Markets Analyst, George Sharp, as Advisor GlobeNewswire "Press Releases"
Richland, WA , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCPINK: RDGL), a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in humans and animals, today announced that it has retained well-known microcap analyst and consultant to OTC Markets Group, George Sharp , as an advisor to the company. Mr. Sharp will advise Vivos on its business strategy, financing endeavors and its commitment to investor interests.
Vivos Inc. President, Mike Korenko , stated, As we discovered from an unsolicited July 17, 2018 article written by George and posted on his blog, George is very supportive of our efforts towards developing cancer treatments, and to date, Vivos remains the only microcap issuer that he has ever endorsed.
Mr. Korenko went on to say, George's experience as an advocate for individual investors in the microcap space, has garnered him a significant following, and his respect is a commodity valued by Vivos. We look forward to Georges continued contribution as we endeavor to execute on the agreements outlined in our previous press release to eliminate the toxic debt and provide critical funding for product development.
Recognizing Mr. Sharps value to the microcap market, OTC Markets Group, an operator of financial markets and provider of the platform on which the shares of Vivos trade, has engaged George's expertise in tracking small and microcap market activity in support of their efforts to improve market transparency.
"I am thrilled for the opportunity to work with Vivos management and I am encouraged by their dedication to create a valuable company that can improve therapeutic results and quality of life for those needing treatment and reward investors for their support of this important effort. This is a genuine a commitment rarely found within the OTC Markets, statedGeorge Sharp. "I look forward to making my small contribution towards finding less invasive treatments for cancer through my continued support of the company."
About Vivos Inc. (OTC: RDGL)
Vivos, Inc. has developed an Yttrium-90 based brachytherapy injectable device, for the treatment of tumors in animals (IsoPet) and in humans (Radiogel). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the companys proprietary hydrogel formulation. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.
IsoPet for treating animals uses the same technology as RadioGelTM for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.
IsoPet is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. This hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial space after injection to keep the radiation source safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
IsoPet also has a short half-life delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to the family.
The IsoPet Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The testing on feline sarcoma at the Washington State University is completed and the testing on canine soft tissue sarcomas at University of Missouri will begin in the near future.
The Company recently obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. Following this demonstration phase, Vivos can begin to generate revenues through the sale of IsoPet to University animal hospitals and private veterinary clinic consortiums.
The Company is also engaging the FDA for clearance to market RadioGel for the treatment of advanced basal and squamous cell skin cancers in humans.
About George Sharp
Drawing from his experiences as a litigant, investigator and forensic researcher, George Sharp consults with attorneys and publicly-traded companies seeking to protect investors. He has appeared on television and referenced in the print media for his efforts to combat microcap fraud. To learn more aboutGeorge Sharp'sservices, visitwww.clippercp.com.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.
CONTACT: Vivos Inc. Michael K. Korenko , President & CEO MKorenko@RadioGel.com
Source: Vivos Inc.
Richland, WA , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCPINK: RDGL), a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in humans and animals, today announced that it has retained well-known microcap analyst and consultant to OTC Markets Group, George Sharp , as an advisor to the company. Mr. Sharp will advise Vivos on its business strategy, financing endeavors and its commitment to investor interests.
Vivos Inc. President, Mike Korenko , stated, As we discovered from an unsolicited July 17, 2018 article written by George and posted on his blog, George is very supportive of our efforts towards developing cancer treatments, and to date, Vivos remains the only microcap issuer that he has ever endorsed.
Mr. Korenko went on to say, George's experience as an advocate for individual investors in the microcap space, has garnered him a significant following, and his respect is a commodity valued by Vivos. We look forward to Georges continued contribution as we endeavor to execute on the agreements outlined in our previous press release to eliminate the toxic debt and provide critical funding for product development.
Recognizing Mr. Sharps value to the microcap market, OTC Markets Group, an operator of financial markets and provider of the platform on which the shares of Vivos trade, has engaged George's expertise in tracking small and microcap market activity in support of their efforts to improve market transparency.
"I am thrilled for the opportunity to work with Vivos management and I am encouraged by their dedication to create a valuable company that can improve therapeutic results and quality of life for those needing treatment and reward investors for their support of this important effort. This is a genuine a commitment rarely found within the OTC Markets, statedGeorge Sharp. "I look forward to making my small contribution towards finding less invasive treatments for cancer through my continued support of the company."
About Vivos Inc. (OTC: RDGL)
Vivos, Inc. has developed an Yttrium-90 based brachytherapy injectable device, for the treatment of tumors in animals (IsoPet) and in humans (Radiogel). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the companys proprietary hydrogel formulation. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.
IsoPet for treating animals uses the same technology as RadioGelTM for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.
IsoPet is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. This hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial space after injection to keep the radiation source safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
IsoPet also has a short half-life delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to the family.
The IsoPet Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The testing on feline sarcoma at the Washington State University is completed and the testing on canine soft tissue sarcomas at University of Missouri will begin in the near future.
The Company recently obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. Following this demonstration phase, Vivos can begin to generate revenues through the sale of IsoPet to University animal hospitals and private veterinary clinic consortiums.
The Company is also engaging the FDA for clearance to market RadioGel for the treatment of advanced basal and squamous cell skin cancers in humans.
About George Sharp
Drawing from his experiences as a litigant, investigator and forensic researcher, George Sharp consults with attorneys and publicly-traded companies seeking to protect investors. He has appeared on television and referenced in the print media for his efforts to combat microcap fraud. To learn more aboutGeorge Sharp'sservices, visitwww.clippercp.com.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.
CONTACT: Vivos Inc. Michael K. Korenko , President & CEO MKorenko@RadioGel.com
Source: Vivos Inc.
